Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LGMN | Q99538 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13125313 | 0.86 | TSHR (0.53) | TSHRSMN1; SMN2KDM4EPOLBALDH1A1 | |
| SCHEMBL1666181 | 0.83 | TSHR (0.57) | TSHRSMN1; SMN2KDM4EPOLBALDH1A1 | |
| SCHEMBL14804179 | 0.83 | MEN1 (0.51) | TSHRSMN1; SMN2KDM4EPOLBALDH1A1 | |
| SCHEMBL1665672 | 0.82 | MAPT (0.53) | TSHRSMN1; SMN2KDM4EALDH1A1MEN1 | |
| SCHEMBL5022271 | 0.79 | ALDH1A1 (0.56) | TSHRSMN1; SMN2KDM4EPOLBALDH1A1 | |
| SCHEMBL14804174 | 0.79 | ALDH1A1 (0.56) | TSHRSMN1; SMN2KDM4EPOLBALDH1A1 | |
| SCHEMBL23582571 | 0.78 | MAPT (0.56) | TSHRSMN1; SMN2KDM4EPOLBALDH1A1 | |
| SCHEMBL14804206 | 0.77 | TSHR (0.67) | TSHRSMN1; SMN2KDM4EPOLBALDH1A1 | |
| SCHEMBL13125258 | 0.77 | ALDH1A1 (0.49) | TSHRSMN1; SMN2KDM4EPOLBALDH1A1 | |
| SCHEMBL7379963 | 0.76 | MAPT (0.60) | TSHRKDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314586-B1 | 2-Acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2016-09-14 | — | — | EP | disclosed |
| US-8765764-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-1466912-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-20130079351-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA, INC. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-8338429-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-12-25 | — | — | US | disclosed |
| EP-2314586-A1 | 2-Acylaminothiazole derivative or salt thereof | Astellas Pharma Inc. (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100222329-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-20100222361-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-7638536-B2 | N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally | ASTELLAS PHARMA INC. (JP) | 2009-12-29 | — | — | US | disclosed |
| US-20050153977-A1 | 2-Acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2005-07-14 | — | — | US | disclosed |
| EP-1466912-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153977-A1 | 2-Acylaminothiazole derivative or salt thereof | MPL, JAK2, ABL1 | TSHR 2796/4885SMN1; SMN2 967/4885KDM4E 1499/4885 |
| US-20130079351-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | TSHR 2796/4885SMN1; SMN2 967/4885KDM4E 1499/4885 |
| US-20100222329-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | TSHR 2796/4885SMN1; SMN2 967/4885KDM4E 1499/4885 |
| US-20100222361-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | TSHR 2796/4885SMN1; SMN2 967/4885KDM4E 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.